High-risk neuroblastoma (HRNB) constitutes approximately 50-60% of all neuroblastoma cases and is associated with poor prognostic indicators such as MYCN amplification, metastatic disease, and unfavorable histology. Here, MYCN is linked to metastatic neoplasm.